Severe COVID-19 and Multisystem Inflammatory Syndrome in Children in Children and Adolescents

Allison M Blatz; Adrienne G Randolph

doi:10.1016/j.ccc.2022.01.005

Severe COVID-19 and Multisystem Inflammatory Syndrome in Children in Children and Adolescents

Crit Care Clin. 2022 Jul;38(3):571-586. doi: 10.1016/j.ccc.2022.01.005. Epub 2022 Jan 10.

Authors

Allison M Blatz¹, Adrienne G Randolph²

Affiliations

¹ Department of Pediatrics, Division of Infectious Diseases, Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA 19104, USA.
² Department of Anesthesiology, Critical Care and Pain Medicine, Division of Critical Care, Boston Children's Hospital, 300 Longwood Avenue, Bader 634, Boston, MA 02115, USA; Department of Anaesthesia and Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Electronic address: [email protected].

Abstract

Severe complications related to COVID-19 occur infrequently in children and adolescents. these life-threatening complications are mainly acute respiratory failure from acute COVID-19 and multisystem inflammatory syndrome in children (MIS-C). MIS-C is a postinfectious complication occurring approximately 3 to 6 weeks mostly after an asymptomatic or mild SARS-CoV-2 infection. For both types of complications, supportive ICU care is often required. For MIS-C critical illness, immunomodulation is prescribed to reverse hyperinflammation and its cardiac and other sequelae.

Keywords: COVID-19; MIS-C; Multisystem inflammatory syndrome; Pediatrics.

Publication types

Review

MeSH terms

Adolescent
COVID-19* / complications
COVID-19* / therapy
Child
Humans
SARS-CoV-2
Systemic Inflammatory Response Syndrome / diagnosis
Systemic Inflammatory Response Syndrome / therapy

Supplementary concepts

pediatric multisystem inflammatory disease, COVID-19 related

Grants and funding

T32 GM075766/GM/NIGMS NIH HHS/United States